Also, the combination of CCR2 and CXCR2 inhibitors can interrupt the accumulation of CCR2+ TAMs and CXCR2+ tumor-associated neutrophils (TANs) in the TME and enhance the effectiveness of chemotherapy in treating PDAC [147]. The gene discussed is CCR2; the disease is neoplasm.